BioMarin's Big Quarter: Fool by Numbers
By
Motley Fool Contributors
February 26, 2007
|
On Feb. 20, BioMarin Pharmaceutical (Nasdaq: BMRN) released fourth-quarter earnings for the period ended Dec. 31.
- Revenues have shot up by 132.4% due to increased revenues from Naglazyme and Aldurazyme.
- The net loss narrowed for the quarter because of better revenues and improvement in margins.
- In January, the company reported positive data for its phase 3 trials of Phenoptin for PKU, a metabolic disease.
- BioMarin announced that the remaining $51.4 million of convertible notes due 2008 was converted into common stock
- The company expects a net loss to the tune of $20 million to $25 million for fiscal 2007, which includes non-cash stock compensation expense of about $16 million to $18 million.
- BioMarin is highly regarded in Motley Fool CAPS, where it sports a four-star rating.
(Figures in millions, except per-share data)
Income Statement Highlights
|
Q4 2006
|
Q4 2005
|
Change
|
|
Sales
|
$22.0
|
$9.5
|
132.4%
|
|
Net Profit
|
($10.4)
|
($15.0)
|
N/A
|
|
EPS
|
($0.11)
|
($0.20)
|
N/A
|
|
Diluted Shares
|
91.6
|
74.0
|
23.6%
|
Get back to basics with a look at the income statement.
Margin Checkup
|
Q4 2006
|
Q4 2005
|
Change*
|
|
Gross Margin
|
83.6%
|
86.0%
|
(2.4)
|
|
Operating Margin
|
(52.5%)
|
(135.4%)
|
82.9
|
|
Net Margin
|
(47.2%)
|
(158.3%)
|
111.1
|
*Expressed in percentage points.
Margins are the earnings engine. See how they work.
Balance Sheet Highlights
|
Assets
|
Q4 2006
|
Q4 2005
|
Change
|
|
Cash + ST Invest.
|
$288.8
|
$47.8
|
504.4%
|
|
Accounts Rec.
|
$14.7
|
$5.9
|
150.3%
|
|
Inventory
|
$25.1
|
$10.9
|
130.1%
|
|
Liabilities
|
Q4 2006
|
Q4 2005
|
Change
|
|
Accounts Payable*
|
$32.2
|
$20.9
|
53.7%
|
|
Long-Term Debt
|
$223.9
|
$125.0
|
79.2%
|
*Accounts payable include accrued liabilities.
Learn the ways of the balance sheet.
Cash Flow Highlights
A statement of cash flows was not provided.
Find out why Fools always follow the money.
Related Foolishness:
Check out our Motley Fool CAPS investor community today. It's fun and free, and could make you a better investor.
Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean. This data has been provided by Netscribes. To provide feedback on this article, please click on the "feedback" button below.